Jan 9, 2026 08:31AM Evolus reports preliminary Q4 2025 revenue of $88.6M to $90.6M

Dec 11, 2025 04:38AM Mizuho Reiterates Outperform Rating on Evolus (EOLS)

Dec 4, 2025 06:39AM Evolus (EOLS) PT Lowered to $19 at Mizuho

Dec 2, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Evolus (EOLS)

Dec 1, 2025 04:34PM Evolus (EOLS) PT Lowered to $19 at Mizuho

Nov 13, 2025 04:36AM Mizuho on Evolus (EOLS): 'Medytox Selling Overhang Could End Soon', 'could enhance the stock's appeal to investors'

Nov 5, 2025 04:40PM Evolus (EOLS) Misses Q3 EPS by 9c ; Offers Guidance

Aug 25, 2025 08:01AM Evolus reports positive trial results for Evolysse Sculpt dermal filler

Aug 21, 2025 06:34AM Mizuho Reiterates Outperform Rating on Evolus (EOLS)

Aug 21, 2025 05:22AM Mizuho Reiterates Outperform Rating on Evolus (EOLS)

Aug 20, 2025 08:01AM Evolus submits FDA application for Evolysse Sculpt dermal filler

Aug 6, 2025 07:18AM Needham Downgrades Evolus (EOLS) to Hold

Aug 6, 2025 07:13AM Evolus (EOLS) PT Lowered to $20 at H.C. Wainwright

Aug 6, 2025 05:59AM Evolus (EOLS) PT Lowered to $18 at BTIG

Aug 5, 2025 04:13PM Evolus (EOLS) Misses Q2 EPS by 17c

Jul 31, 2025 08:06AM Study finds Evolus Jeuveau shows fast onset among four neurotoxins

May 30, 2025 08:40AM Stifel Reiterates Buy Rating on Evolus (EOLS)

May 28, 2025 05:28AM Mizuho on Evolus (EOLS): 'We recommend buying on any potential weakness'

May 27, 2025 04:16PM Evolus (EOLS) Announces CFO Departure

May 22, 2025 08:01AM Evolus (EOLS) Announces Publication of U.S. Pivotal Study for Evolysse Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

May 7, 2025 04:30PM Evolus (EOLS) Misses Q1 EPS by 21c, Misses on Revenue; Offers FY25 Revenue Guidance

May 5, 2025 04:15PM Evolus (EOLS) Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility

Apr 17, 2025 05:38AM BTIG Starts Evolus (EOLS) at Buy

Apr 10, 2025 06:37AM H.C. Wainwright Reiterates Buy Rating on Evolus (EOLS)

Mar 5, 2025 09:21AM Stifel Reiterates Buy Rating on Evolus (EOLS)

Mar 5, 2025 06:48AM H.C. Wainwright Reiterates Buy Rating on Evolus (EOLS)

Mar 4, 2025 04:08PM Evolus (EOLS) Misses Q4 EPS by 13c, Beats on Revenue; Offers FY25 Revenue Guidance

Feb 13, 2025 01:32PM Evolus (EOLS) Announces FDA Approval of Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels

Jan 21, 2025 10:31AM Stifel Reiterates Buy Rating on Evolus (EOLS)

Jan 21, 2025 08:04AM Evolus (EOLS) Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue

Nov 6, 2024 04:31PM Evolus (EOLS) Misses Q3 EPS by 18c ; Offers Guidance

Oct 31, 2024 02:02PM Evolus (EOLS) Announces EU Approval of Estyme Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Oct 3, 2024 06:57AM H.C. Wainwright Reiterates Buy Rating on Evolus (EOLS)

Sep 13, 2024 05:11AM Evolus (EOLS) PT Raised to $25 at Mizuho

Sep 9, 2024 06:38AM Mizuho Reiterates Outperform Rating on Evolus (EOLS)

Aug 21, 2024 05:15AM Mizuho Reiterates Outperform Rating on Evolus (EOLS)

Jul 31, 2024 04:25PM Evolus (EOLS) Misses Q2 EPS by 13c ; Offers Guidance

Jul 30, 2024 08:03AM Evolus (EOLS) Expands Global Footprint with Introduction of Nuceiva in Australia

Jul 1, 2024 08:04AM Evolus (EOLS) Appoints Albert G. White III to its Board

Jun 24, 2024 08:00AM Evolus (EOLS) Announces Submission of Premarket Approval Application to the FDA for First Two Evolysse Dermal Filler Products